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Figure 2. Relative expression of FGF1 mRNA under different culture
conditions in co- and mono-cultures of hMSCs and hPCs.
Note: the ﬁrst two authors contributed equally to this work.
Figure 1. A rug-plot of bivariate scatters of ARGS-aggrecan concentrations
in SF, serum, plasma and urine from 36 subjects at different times over 5
years after ACL injury. Concentrations in urine are given corrected for
urinary creatinine. Filled circles are concentrations measured within the
detection limits of the ARGS-aggrecan assay. Open circles are urinary
ARGS concentration below the assay Lower Limit Of Quantiﬁcation (LLOQ;
0.025 pmol/ml) that were imputed to half the LLOQ value. Linear
regression lines (solid) with 95% conﬁdence intervals (long dashed) are
indicted in each scatter plot. In the rug-plot, each bivariate scatter plot
shares information of one variate with the adjacent plot, illustrated by
interconnecting rug fringes showing the marginal distribution of the
shared variate. Horizontal and vertical lines (short dashed) interconnect
ARGS concentrations in different bivariate combinations of ﬂuids in one
subject. All scales are logarithmic and reﬂect the range of ARGS concen-
trations in each ﬂuid.
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ARGS-AGGRECAN QUANTIFICATION IN SYNOVIAL FLUID, SERUM,
PLASMA AND URINE - AN ASSAY VALIDATION
S. Larsson y, S. Lohmander y,z, A. Struglics y. yDept. of Orthopaedics,
Clinical Sci. Lund, Lund Univ., Lund, Sweden; zRes. Unit for
Musculoskeletal Function and Physiotherapy, and Dept. of Orthopaedics
and Traumatology, Univ. of Southern Denmark, Odense, Denmark
Purpose: Aggrecanase cleavage at the 392Glu-393Ala bond in the
interglobular domain of aggrecan, releasing N-terminal 393ARGS
fragments into synovial ﬂuid (SF), is an early key event in arthritis
and joint injuries. We have shown that SF-ARGS is associated with
radiographic progression of knee osteoarthritis (OA) as well as with
progression of self-reported pain after meniscectomy. Our objective
was to validate a modiﬁed ligand-binding assay for the detection of
aggrecanase generated aggrecan fragments with the ARGS neo-
epitope in SF, blood and urine, and to verify the identity of aggrecan
fragments found in blood.
Methods: A sandwich enzyme-linked immunosorbent assay (ELISA) on
the Meso Scale Discovery (MSD) platform for detection of ARGS-
aggrecanwas validated, using a standard made by ADAMTS-4-digestion
of recombinant human aggrecan (1220-PG, R&D Systems), an anti-
aggrecan antibody (AHP0022, Invitrogen) for capture, and amonoclonal
anti-ARGS (OA-1, GlaxoSmithKline) for detection. We analysed recovery
to dilution and spiking of equimolar concentrations of standard in SF
and serum samples. Matched samples of SF, serum, plasma, and urine
were obtained from 36 subjects at different time points 0 to 5 years
after an anterior cruciate ligament (ACL) tear, and analysed for ARGS-
aggrecan content. Aggrecan was puriﬁed by caesium chloride density
gradient centrifugation from serum and plasma pools and analysed by
Western blot using the anti-ARGS antibody. We used Spearman’s rank
order correlation (rS) for assessment of correlation, based on Shapiro-
Wilk test indicating skewed distributions of a majority of the variables.
Results: The limits of quantiﬁcation for the ARGS-aggrecan assay was
between 0.2 and 0.025 pmol ARGS/ml. Inside these limits recovery to
dilution was, mean (range) 100% (83-117%), and to spiking 89% (77-
110%). The sensitivity of the assay was improved 2-fold compared to
when using a standard puriﬁed from human donors. The ARGS con-
centrations were highest in SF (mean, range; 3.02, 0.36 - 30.22 pmol/
ml), 20 times lower in the blood samples (0.14, 0.055 - 0.28 pmol/ml
serum and 0.13, 0.053 - 0.28 pmol/ml plasma), and 80 times lower in
urine (0.036, <0.025 - 0.087 pmol/ml). Serum-ARGS and plasma-ARGS
concentrations were similar, and correlated (Figure 1: rS ¼ 0.773). SFconcentrations correlated with serum and plasma concentrations
(Figure 1: rS ¼ 0.420 and 0.386, respectively). In puriﬁed serum and
plasma samples, we identiﬁed 129-138 kDa aggrecan fragments con-
taining the ARGS neoepitope.Conclusions: This novel ARGS-aggrecan assay is highly sensitive and
suited for analysis of SF and blood samples. Both SF and blood contains
ARGS-aggrecan, and ARGS concentrations in SF and blood are correla-
ted.
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SPECIFIC PEPTIDE DISTRIBUTION IN HUMAN OSTEOARTHRITIC
SYNOVIAL MEMBRANES REVEALS DIFFERENT GRADES OF TISSUE
INFLAMMATION
B. Cillero-Pastor y, G. Eijkel y, F. Blanco z, R. Heeren y. yAMOLF-FOM Inst.,
Amsterdam, Netherlands; zRheumatology Div.. Proteomic Group. Proteo-
Red-ISCIII. INIBIC-Hosp. Univ.rio A Coru~na, A Coru~na, Spain
Purpose: The synovial membrane is an important source for biomarker
discovery of many rheumatic pathologies. The heterogeneity of osteo-
arthritis (OA) affected tissues and the spatial distribution of proteins in
the human synovial membrane is poorly studied. The speciﬁc protein
and peptide proﬁles in different areas of the synovial tissue can reveal
information about the underlying pathways that play a role in the OA
pathology. The distribution of these speciﬁc protein/peptide proﬁles
can be used for tissue/patient classiﬁcation. Matrix assisted laser
desorption ionization mass spectrometric imaging (MALDI-MSI) is a
novel technique that can be employed to reveal the molecular signature
of a region or area of interest in a biological tissue. In this work, we have
studied the peptide proﬁles and their distributions in human normal
and OA synovial membranes.We have described speciﬁc OA biomarkers
commonly found in cartilage and synovial tissues by MALDI-MSI.
